Enterprise Value
919.8M
Cash
396.9M
Avg Qtr Burn
-39.19M
Short % of Float
18.96%
Insider Ownership
7.14%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KT-474 (IRAK4 degrader) Details Hidradenitis suppurativa, Rheumatoid arthritis, Atopic dermatitis | Phase 2 Initiation | |
KT-253 Details Solid tumor/s | Phase 1 Data readout | |
KT-333 Details Solid tumor/s, Cancer | Phase 1 Data readout | |
KT-413 Details Solid tumor/s | Phase 1 Data readout |